Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Revenue (2020 - 2025)

Maxcyte (MXCT) has disclosed Revenue for 6 consecutive years, with $4.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 17.98% to $4.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.1 million, a 28.21% decrease, with the full-year FY2024 number at $22.2 million, up 13.94% from a year prior.
  • Revenue was $4.6 million for Q3 2025 at Maxcyte, down from $8.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $12.7 million in Q2 2023 to a low of $296000.0 in Q4 2024.
  • A 5-year average of $7.0 million and a median of $6.5 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 4415.79% in 2021, then tumbled 93.78% in 2024.
  • Maxcyte's Revenue stood at $10.2 million in 2021, then fell by 23.6% to $7.8 million in 2022, then plummeted by 38.69% to $4.8 million in 2023, then crashed by 93.78% to $296000.0 in 2024, then surged by 1455.07% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Revenue are $4.6 million (Q3 2025), $8.5 million (Q2 2025), and $5.7 million (Q1 2025).